NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Price, News & Analysis → Strange new buyer driving up gold (From Stansberry Research) (Ad) Free AVTE Stock Alerts $21.99 +0.39 (+1.81%) (As of 03:26 PM ET) Add Compare Share Share Today's Range$20.73▼$22.4150-Day Range$18.80▼$30.7552-Week Range$9.41▼$32.42Volume156,046 shsAverage Volume129,949 shsMarket Capitalization$612.64 millionP/E RatioN/ADividend YieldN/APrice Target$49.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aerovate Therapeutics alerts: Email Address Aerovate Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside122.6% Upside$49.33 Price TargetShort InterestBearish5.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 10 Articles This WeekInsider TradingSelling Shares$2.03 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.78) to ($2.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.56 out of 5 starsMedical Sector661st out of 918 stocksPharmaceutical Preparations Industry296th out of 419 stocks 3.5 Analyst's Opinion Consensus RatingAerovate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAerovate Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.78% of the float of Aerovate Therapeutics has been sold short.Short Interest Ratio / Days to CoverAerovate Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Aerovate Therapeutics has recently increased by 9.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAerovate Therapeutics does not currently pay a dividend.Dividend GrowthAerovate Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTE. Previous Next 3.7 News and Social Media Coverage News SentimentAerovate Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Aerovate Therapeutics this week, compared to 1 article on an average week.Search Interest9 people have searched for AVTE on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Aerovate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aerovate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,033,870.00 in company stock.Percentage Held by Insiders19.30% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aerovate Therapeutics are expected to decrease in the coming year, from ($2.78) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerovate Therapeutics is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerovate Therapeutics is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAerovate Therapeutics has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchStrange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."But there's a much better move you can make to get in front of these big moves today. About Aerovate Therapeutics Stock (NASDAQ:AVTE)Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More AVTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTE Stock News HeadlinesApril 19, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Sells $247,000.00 in StockApril 13, 2024 | insidertrades.comInsider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 7,500 Shares of StockApril 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."April 12, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Director Sells $334,478.30 in StockApril 4, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Benjamin T. Dake Sells 3,325 SharesMarch 29, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Benjamin T. Dake Sells 11,068 SharesMarch 28, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 3,432 SharesMarch 21, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $138,224.00 in StockApril 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."April 17, 2024 | americanbankingnews.comShort Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Grows By 9.9%April 14, 2024 | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $201,375.00 in StockApril 13, 2024 | americanbankingnews.comDavid S. Grayzel Sells 11,882 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) StockApril 13, 2024 | americanbankingnews.comAerovate Therapeutics (NASDAQ:AVTE) Shares Down 5.4% After Insider SellingApril 12, 2024 | americanbankingnews.comAerovate Therapeutics (NASDAQ:AVTE) Shares Gap Down to $28.05April 4, 2024 | finance.yahoo.comAerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 SharesApril 2, 2024 | markets.businessinsider.comAerovate Therapeutics: Poised for Market Capitalization Growth on IMPAHCT Trial SuccessApril 1, 2024 | msn.comAerovate Therapeutics (NASDAQ:AVTE) on the Verge of Substantial GrowthMarch 27, 2024 | globenewswire.comAerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceMarch 27, 2024 | finance.yahoo.comAerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023March 26, 2024 | finanznachrichten.deAerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 26, 2024 | markets.businessinsider.comAerovate Therapeutics: A Strong Buy Ahead of Key Clinical Data ReleaseMarch 25, 2024 | benzinga.comRecap: Aerovate Therapeutics Q4 EarningsMarch 25, 2024 | investorplace.comAVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023March 25, 2024 | markets.businessinsider.comAerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 25, 2024 | globenewswire.comAerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 24, 2024 | morningstar.comAerovate Therapeutics Inc AVTEMarch 21, 2024 | finance.yahoo.comInsider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...See More Headlines Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today4/19/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVTE CUSIPN/A CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Target$49.33 High Stock Price Target$65.00 Low Stock Price Target$35.00 Potential Upside/Downside+128.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.62% Return on Assets-55.08% Debt Debt-to-Equity RatioN/A Current Ratio7.04 Quick Ratio7.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book5.45Miscellaneous Outstanding Shares27,860,000Free Float22,483,000Market Cap$601.78 million OptionableNot Optionable Beta1.23 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Timothy P. Noyes M.B.A. (Age 62)CEO & Director Comp: $703.8kMr. George A. Eldridge (Age 61)CFO & Treasurer Comp: $533.89kDr. Marinus Verwijs Ph.D. (Age 48)Chief Technical Officer Comp: $439.88kDr. Benjamin T. Dake Ph.D. (Age 48)Founder, President, COO & Secretary Comp: $435.5kDr. Ralph W. Niven M.B.A. (Age 64)M.R, Ph.D., Pharm.S, Chief Scientific Officer Comp: $372.33kMr. Hunter Gillies M.D. (Age 58)Chief Medical Officer Comp: $512.74kMr. Timothy J. Pigot (Age 53)Chief Commercial Officer Ms. Donna DeaHead of Regulatory AffairsMs. Susan FischerExecutive Vice President of Development OperationsMr. Stephen K. YuSenior Vice President of QualityMore ExecutivesKey CompetitorsLongboard PharmaceuticalsNASDAQ:LBPHBicycle TherapeuticsNASDAQ:BCYCY-mAbs TherapeuticsNASDAQ:YMABPharming GroupNASDAQ:PHARORIC PharmaceuticalsNASDAQ:ORICView All CompetitorsInsiders & InstitutionsTimothy P. NoyesSold 10,000 sharesTotal: $247,000.00 ($24.70/share)George A EldridgeSold 7,500 sharesTotal: $201,375.00 ($26.85/share)David S GrayzelSold 11,882 sharesTotal: $334,478.30 ($28.15/share)Benjamin T DakeSold 3,325 sharesTotal: $106,300.25 ($31.97/share)Timothy P. NoyesSold 10,000 sharesTotal: $300,000.00 ($30.00/share)View All Insider TransactionsView All Institutional Transactions AVTE Stock Analysis - Frequently Asked Questions Should I buy or sell Aerovate Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVTE shares. View AVTE analyst ratings or view top-rated stocks. What is Aerovate Therapeutics' stock price target for 2024? 3 equities research analysts have issued 12 month target prices for Aerovate Therapeutics' shares. Their AVTE share price targets range from $35.00 to $65.00. On average, they anticipate the company's stock price to reach $49.33 in the next year. This suggests a possible upside of 122.6% from the stock's current price. View analysts price targets for AVTE or view top-rated stocks among Wall Street analysts. How have AVTE shares performed in 2024? Aerovate Therapeutics' stock was trading at $22.63 on January 1st, 2024. Since then, AVTE stock has decreased by 2.1% and is now trading at $22.16. View the best growth stocks for 2024 here. Are investors shorting Aerovate Therapeutics? Aerovate Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 993,100 shares, an increase of 9.9% from the March 15th total of 903,700 shares. Based on an average daily trading volume, of 130,200 shares, the short-interest ratio is presently 7.6 days. Currently, 5.8% of the company's stock are sold short. View Aerovate Therapeutics' Short Interest. When is Aerovate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our AVTE earnings forecast. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) posted its quarterly earnings results on Sunday, November, 14th. The company reported ($0.26) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.26). When did Aerovate Therapeutics IPO? Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVTE) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 MediaMy biggest AI fearParadigm PressHow Biden has already won 2024Porter & CompanyOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.